H1 Blog

SEPTEMBER 26, 2023

Breaking Down Barriers to International Clinical Trials Global Disruptions, Health Equity & Data Sharing As the U.S. A recent McKinsey analysis of drugs and vaccines developed since 2000 shows that it takes nearly ten years to go from clinical testing to approval. First let’s look at some challenges and then opportunities.

Trials 59

Trials Clinical Trials International Regulations 59

H1 Blog

JULY 30, 2024

Increasing diversity in clinical trials not only makes the findings more relevant to various patient groups, but also enhances knowledge about the disease or medical product being studied. This allows the trial to achieve more precise results at the indication level through leveraging comprehensive information from across the globe.

FDA 59

FDA Clinical Trials Compliance Pharma Companies 59

H1 Blog

JULY 5, 2023

The success of drug development and approval relies heavily on the ability to identify diverse patient populations for clinical trials. From trial site feasibility to successful trial recruitment, diversity within a trial population helps ensure the safety and efficacy of drugs that reach the market.

Clinical Trials 52

Clinical Trials Drugs Trials Drug Development 52

H1 Blog

JUNE 8, 2023

In this blog post, we’ll explore how early diversity in HCP engagement can drive better outcomes and equity in drug development. The drug development process is known to be often expensive, lengthy, and full of trial and error before finding success.

Drug Development 52

Drug Development Science Pharmaceutical Companies Production 52

H1 Blog

NOVEMBER 29, 2023

Breaking the Barriers: How Inaccurate Trial Records Are Delaying Drug Development and Limiting Diverse Patient Populations In an October 2023 report , BMC Medicine completed a follow-up on a 10-year effort to understand, report on and track data sharing challenges with big pharma, specifically for clinical trials.

Clinical Trials 59

Clinical Trials Trials Drug Development Treatment 59